Mesoridazine Besylate

Drug #1987

Mesoridazine besylate, the besylate salt of a metabolite of thioridazine, is a phenothiazine tranquilizer which is effective in the treatment of schizophrenia, organic brain disorders, alcoholism and psychoneuroses. Mesoridazine besylate is 10 [2(1-methyl 2-piperidyl) ethyl]-2-(methyl-sulfinyl)-phenothiazine [as the besylate].

← Previous drug Next drug →

Primary Characteristics

It belongs to Phenothiazine.

Molecular Weight: 544.7 · Solubility in Water: 1 in 1 · Solubility in Alcohol: 1 in 11 · Non-proprietary name: Mesoridazine Besylate.

Molecular structure of Mesoridazine Besylate

Pharmacokinetics

Distribution: Mesoridazine Besylate has a plasma protein binding is 4%.

Elimination: it is metabolised via Hepatic, plasma half-life is 28-48 hrs.

Indications

Mesoridazine Besylate is primarily indicated in conditions like Schizophrenia.

Mesoridazine Besylate is also indicated for secondary conditions like Chronic alcoholism, Hyperactivity.

Contraindications

Mesoridazine Besylate is contraindicated in conditions like CNS depression, Hypersensitivity to the drug.

Dosage

Mesoridazine Besylate's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
50 mg	50 mg	—	PO	Starting dose
250 mg	250 mg	—	PO	The usual optimum total daily dose range .
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

1 interaction

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Mesoridazine Besylate produces potentially life-threatening effects which include Arrhythmias. Careful monitoring is needed with proper medical management.

The signs and symptoms that are produced after acute overdosage of Mesoridazine Besylate are Vomiting, Edema, Tachycardia , Coma, Dilated pupils, Ataxia, Tremor, Agitation, Congestive heart failure, Dystonia.

Mesoridazine Besylate is known to cause more or less tolerable side effects which are usually transient. These include Constipation , Drowsiness, Dry mouth, Hypotension , Vomiting .

Warnings / Precautions

While ocular changes have not to date been related to Mesoridazine besylate, one should be aware that such changes have been seen with other drugs of this class. Because of ponoible hypotensive effects, reserve parenteral administration for bedfast patients or for acute ambulatory cases, and keep patient lying down for at least one-half hour after injection. Leokopenia and/or agranulocytosis have been attributed to phenothiazine therapy. A single case of transient granulocytopenia has been associated with mesoridazine besylate. Since convulsive seizures have been reported, patients receiving anticonvulsant medication should be maintained on that regimen while receiving mesoridazine besylate.

Available Brands

None recorded.

Drug Classification

1.24.1 — Drugs used in psychotic disorders